Φορτώνει......
Tadalafil therapy for sarcoidosis-associated pulmonary hypertension
Abstract. Sarcoidosis-associated pulmonary hypertension (SAPH) is estimated to occur in at least 5% or more of sarcoidosis patients, and it contributes to significant morbidity and mortality. Optimal therapy for SAPH is not well established. We performed a 24-week open-label trial of tadalafil for S...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Pulm Circ |
|---|---|
| Κύριοι συγγραφείς: | , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
University of Chicago Press
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5210066/ https://ncbi.nlm.nih.gov/pubmed/28090299 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1086/688775 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|